Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.49 |
| ▸ | SPR | P35270 | 1/20 | 0.48 |
| ▸ | CKS1B | P61024 | 2/20 | 0.48 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | ACLY | P53396 | 1/20 | 0.44 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4504852 | 0.92 | HSD17B2 (0.53) | HSD17B2SCN9ASPRCKS1BSKP2 | |
| SCHEMBL4500780 | 0.88 | HSD17B2 (0.51) | HSD17B2SCN9ASPRCKS1BSKP2 | |
| SCHEMBL4503315 | 0.88 | BRD4 (0.52) | SCN9ASPRSLC22A12BRD4SLC40A1 | |
| SCHEMBL4489474 | 0.85 | HSD17B2 (0.49) | HSD17B2SCN9ASPRCKS1BSKP2 | |
| SCHEMBL4500689 | 0.85 | PKM (0.48) | SCN9ASLC22A12BRD4 | |
| SCHEMBL5918340 | 0.84 | SCN9A (0.43) | HSD17B2SCN9ASPRNR3C1AR | |
| SCHEMBL4506739 | 0.84 | HSD17B2 (0.53) | HSD17B2CKS1BSKP2PIK3CBTSHR | |
| SCHEMBL4493655 | 0.81 | KDM1A (0.53) | SCN9ACKS1BSKP2PIK3CBTSHR | |
| SCHEMBL4497259 | 0.81 | MEN1 (0.51) | SCN9ACKS1BSKP2PIK3CBTSHR | |
| SCHEMBL4506414 | 0.80 | SCN9A (0.45) | HSD17B2SCN9ASPRCKS1BSKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211913-B2 | 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-07-03 | — | — | US | claimed |
| CN-100589803-C | Aryl-pyridine derivatives | HOFFMANN LA ROCHE | 2010-02-17 | — | — | CN | claimed |
| US-20090149503-A1 | NEW 5-ARYL PYRIDINES AS 11-BETA INHIBITORS FOR THE TREATMENT OF DIABETES | AMREIN KURT | 2009-06-11 | — | — | US | claimed |
| US-7528159-B2 | 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | claimed |
| EP-1789041-B1 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | claimed |
| CN-1988905-A | Aryl-pyridine derivatives | HOFFMANN LA ROCHE (CH) | 2007-06-27 | — | — | CN | claimed |
| EP-1789041-A2 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-05-30 | — | — | EP | claimed |
| US-20060025455-A1 | New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. | 2006-02-02 | — | — | US | claimed |
| WO-2006010546-A2 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | F. HOFFMAN-LA ROCHE AG (CH) | 2006-02-02 | — | — | WO | claimed |
| US-8211913-B2 | 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-07-03 | — | — | US | disclosed |
| CN-100589803-C | Aryl-pyridine derivatives | HOFFMANN LA ROCHE | 2010-02-17 | — | — | CN | disclosed |
| US-20090149503-A1 | NEW 5-ARYL PYRIDINES AS 11-BETA INHIBITORS FOR THE TREATMENT OF DIABETES | AMREIN KURT | 2009-06-11 | — | — | US | disclosed |
| US-7528159-B2 | 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1789041-B1 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | disclosed |
| CN-1988905-A | Aryl-pyridine derivatives | HOFFMANN LA ROCHE (CH) | 2007-06-27 | — | — | CN | disclosed |
| EP-1789041-A2 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-05-30 | — | — | EP | disclosed |
| US-20060025455-A1 | New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. | 2006-02-02 | — | — | US | disclosed |
| WO-2006010546-A2 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | F. HOFFMAN-LA ROCHE AG (CH) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149503-A1 | NEW 5-ARYL PYRIDINES AS 11-BETA INHIBITORS FOR THE TREATMENT OF DIABETES | GPR119, CYP4B1, SLC5A1 | HSD17B2 175/4885SCN9A 925/4885SPR 905/4885 |
| US-20060025455-A1 | New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | GPR119, CYP4B1, SLC5A1 | HSD17B2 175/4885SCN9A 925/4885SPR 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.